Although the first‐line treatment of MAS mostly relies on corticosteroids and cyclosporine and data on the use of cytokine blockade strategies, are controversial,32 the role of biologic agents (including anti‐IL‐1 and anti‐IL‐6 drugs) in the therapeutic approach to MAS is still being investigated in clinical trils.32, 33. The gene discussed is IL6; the disease is macrophage activation syndrome.